Market capitalization | CHF18.65b |
Enterprise Value | CHF20.73b |
P/E (TTM) P/E ratio | 92.25 |
EV/FCF (TTM) EV/FCF | 66.05 |
EV/Sales (TTM) EV/Sales | 5.34 |
P/S ratio (TTM) P/S ratio | 4.80 |
P/B ratio (TTM) P/B ratio | 2.64 |
Dividend yield | 0.19% |
Last dividend (FY25) | CHF0.15 |
As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.
12 Analysts have issued a Galderma forecast:
12 Analysts have issued a Galderma forecast:
Dec '24 |
+/-
%
|
||
Revenue | 3,884 3,884 |
6%
6%
|
|
Gross Profit | 2,691 2,691 |
5%
5%
|
|
EBITDA | 828 828 |
8%
8%
|
EBIT (Operating Income) EBIT | 570 570 |
10%
10%
|
Net Profit | 202 202 |
500%
500%
|
In millions CHF.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Galderma Group AG engages in the provision of science-based premium dermatology solutions. The firm is also involved in delivering a synergistic portfolio of flagship brands spanning the full spectrum of the fast-growing self-care dermatology market. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Head office | Switzerland |
CEO | Flemming Ørnskov |
Website | www.galderma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.